Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2019
Reporting Period: Events occurring between November 19, 2019, and November 21, 2019.
Context: The Company announced and priced a public offering of Class A common stock and entered into related definitive agreements.
Key Financial Metrics
This filing details a capital raise event rather than periodic operating results. Specific metrics include:
- Offering Size: 9,000,000 shares of Class A common stock (Firm Shares).
- Offering Price: $5.00 per share to the public.
- Expected Net Proceeds: Approximately $41.8 million (after underwriting discounts, commissions, and expenses).
- Over-Allotment Option: Underwriters granted an option to purchase up to 1,350,000 additional shares.
- Related Fees: A fee of approximately $1.7 million is payable to the Management Company of Avista Capital Partners in connection with their purchase of 6,000,000 shares.
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change is the execution of an Underwriting Agreement dated November 21, 2019, with Credit Suisse Securities (USA) LLC and SVB Leerink LLC. This agreement facilitates the sale of the Firm Shares, with the transaction expected to consummate on November 26, 2019. Additionally, the Company entered into a fee letter agreement with Avista Capital Partners regarding their participation in the offering.
Guidance, Outlook, and Risks
- Management Commentary: The Company utilized a shelf registration statement (Form S-3) filed in September 2019 to execute this offering.
- Related Party Transaction: Joshua Tamaroff, a director of the Company, is an employee of the Management Company receiving the $1.7 million fee. The underwriters agreed to waive their discount on the portion of shares sold to the Avista Funds.
- Contingencies: The sale of shares is subject to the satisfaction of conditions set forth in the Underwriting Agreement.
- Risks: The filing includes standard indemnification agreements with underwriters regarding liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the offering (expected November 26, 2019) and the actual net proceeds received.
- Confirm whether the underwriters exercised the option to purchase the additional 1,350,000 shares.
- Review the final prospectus supplement for updated use of proceeds and risk factors.
- Monitor the impact of the $1.7 million fee payment on the Company's immediate cash position.
- Check subsequent filings for any changes in the Company's capital structure or debt levels resulting from this transaction.